Khlystun V. Substantiation of the use of endobronchial therapy in patients with chemo-resistant pulmonary tuberculosis with lesions of bronchial mucosa

Object of study: pulmonary chemo-resistant tuberculosis (CRTB); methods of investigation: clinical, rentgenological, microbiological, instrumental, statistical; the novelty: scientific data on the nature of changes in bronchial mucosa, drainage function of bronchi and features of the pulmonary CRTB with lesions of the bronchial mucosa are supplemented indicating that the presence of lesion of bronchial mucous membrane in patients with pulmonary CRTB; reasonability of endobronchial administration of antituberculous agent isoniazid hydroxymethylhinoalsoxide into the drainage B6 bronchus in patients with pulmonary CRTB and destruction of S6 of the lung and lesion of bronchial mucous membrane; reasonability of endobronchial administration of antimycobacterial drug sensitive to Mycobacterium tuberculosis into B1, B2 (B1+2) drainage bronchi in patients with pulmonary CRTB with destruction of S 1 + 2 of the lung and lesion of bronchial membrane of B1, B2 (B1+2) bronchi with subsequent imposition of intraorganic electrophoresis on area of S1 + 2 of the lung; reasonability of the use of purulent endobronchitis therapy in patients with pulmonary CRTB with destruction in S1+2 or S6 of the lung by the inclusion of a broad spectrum antibiotics doxycycline and mucolytic amoxicol hydrochloride in the complex therapy; it is established that the use of endobronchial therapy in patients with pulmonary CRTB with lesion of the bronchial mucosa contributes to the increase of rate bronchial drainage function normalization; reasonability of use of specific and non-specific endobronchial therapy in patients with pulmonary CRTB with bronchial mucosal lesions which contributes to the increase of treatment by 22%, is substantiated. Scope – medicine.